Index
S&P 500
Market Cap
91.96B
Enterprise Value
-
Income
5.14B
Sales
201.83B
Book/sh
206.75
Cash/sh
-
Employees
97100
IPO
Oct 30, 2001
P/E
18.14
Forward P/E
14.07
PEG
3.09
P/S
0.46
P/B
2.06
P/C
-
P/FCF
14.12
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
1.47
Debt/Eq
0.69
LT Debt/Eq
0.68
Option/Short
Yes / Yes
EPS (ttm)
23.46
EPS next Y
30.25
EPS next Q
2.08
EPS this Y
-4.09%
EPS next Y
4.12%
EPS next 5Y
4.55%
EPS past 3/5Y
1.27% 6.99%
Sales past 3/5Y
8.34% 10.32%
EPS Y/Y TTM
-4.06%
Sales Y/Y TTM
3.60%
EPS Q/Q
18.02%
Sales Q/Q
1.42%
Insider Own
0.23%
Insider Trans
-2.01%
Inst Own
94.78%
Inst Trans
-0.37%
ROA
4.10%
ROE
11.60%
ROIC
6.85%
Gross Margin
-
Oper. Margin
3.81%
Profit Margin
2.55%
SMA20
-0.44%
SMA50
3.09%
SMA200
13.92%
Trades
Shs Outstand
216.11M
Shs Float
215.55M
52W High
450.69 -5.56%
52W Low
274.84 54.86%
Volatility
4.07% 3.17%
ATR (14)
13.30
RSI (14)
53.12
Beta
0.61
Rel Volume
1.21
Avg Volume
1.20M
Volume
1,443,883
Perf Week
1.32%
Perf Month
6.16%
Perf Quarter
7.02%
Perf Half Y
12.58%
Perf YTD
21.41%
Perf Year
35.36%
Perf 3Y
-6.36%
Perf 5Y
0.84%
Perf 10Y
256.79%
Prev Close
432.00
Price
425.62
Change %
-1.48%
Analysts 13 incl. previous ratings
Rating Distribution 6 Buy · 7 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside May 20, 2026 Upgrade D Deutsche Bank
Hold → Buy $498 +17.0% Apr 29, 2026 Upgrade B BofA Securities
Neutral → Buy $435 +2.2% Apr 08, 2026 Initiated E Evercore ISI
In-line $345 -18.9% Feb 03, 2026 Downgrade R RBC Capital Mkts
Outperform → Sector Perform $358 -15.9% Jan 08, 2026 Upgrade W Wolfe Research
Peer Perform → Outperform $425 -0.1% Dec 19, 2025 Downgrade D Deutsche Bank
Buy → Hold $320 -24.8% Oct 14, 2025 Initiated G Goldman
Neutral Jul 21, 2025 Downgrade A Argus
Buy → Hold Jul 18, 2025 Downgrade L Leerink Partners
Outperform → Market Perform $310 -27.2% Apr 15, 2025 Downgrade R Robert W. Baird
Outperform → Neutral $529 +24.3% Mar 17, 2025 Upgrade A Argus
Hold → Buy $450 +5.7% Jan 22, 2025 Downgrade S Stephens
Overweight → Equal-Weight $520 → $440 +3.4% Oct 18, 2024 Downgrade A Argus
Buy → Hold Jul 18, 2024 Downgrade B BofA Securities
Buy → Neutral $646 → $530 +24.5% Jun 24, 2024 Initiated M Morgan Stanley
Overweight $643 +51.1% May 30, 2024 Initiated R Robert W. Baird
Outperform $649 +52.5% Mar 06, 2024 Initiated B Barclays
Overweight $584 +37.2% Jul 12, 2023 Downgrade W Wolfe Research
Outperform → Peer Perform Apr 27, 2023 Upgrade M Morgan Stanley
Equal-Weight → Overweight $500 → $571 +34.2% Apr 21, 2023 Initiated C Cantor Fitzgerald
Overweight $547 +28.5%
Show Previous Ratings
Nov-04-26 10:06AM
09:14AM
Oct-21-26 04:46PM
11:06AM
09:53AM
07:30AM
Loading…
07:30AM
07:03AM
(The Wall Street Journal)
06:40AM
06:07AM
06:00AM
06:00AM
Oct-16-26 10:54AM
Oct-15-26 09:14AM
Oct-13-26 06:03AM
Oct-12-26 03:45PM
09:41AM
Loading…
09:41AM
Oct-09-26 09:13AM
Oct-05-26 08:00AM
Oct-02-26 04:24AM
Oct-01-26 07:00AM
Sep-30-26 02:39PM
Sep-29-26 02:25PM
Sep-24-26 12:34PM
Sep-23-26 05:06PM
12:26PM
Sep-22-26 02:09PM
Sep-18-26 08:15AM
Sep-16-26 01:16PM
Sep-14-26 05:10PM
03:41PM
09:38AM
Loading…
Sep-11-26 09:38AM
Sep-10-26 04:30PM
03:36PM
07:04AM
Sep-09-26 03:30PM
Sep-03-26 01:35PM
10:45AM
Aug-31-26 02:25PM
Aug-28-26 02:06PM
Aug-27-26 07:26PM
Aug-25-26 05:27AM
Aug-24-26 01:04PM
Aug-21-26 04:58PM
Aug-13-26 05:50PM
05:14PM
05:09PM
Aug-07-26 04:40PM
Aug-05-26 11:50AM
Aug-03-26 04:17PM
Jul-31-26 10:36AM
03:00AM
Jul-24-26 04:56PM
Jul-22-26 04:45PM
Jul-21-26 05:26PM
04:33PM
Jul-20-26 10:43AM
Jul-17-26 06:20PM
06:09PM
06:02PM
Jul-16-26 10:54AM
09:19AM
08:30AM
08:30AM
Jul-15-26 05:00PM
04:30PM
09:36AM
08:59AM
(Investor's Business Daily)
08:29AM
07:21AM
06:48AM
06:44AM
(The Wall Street Journal)
06:10AM
06:00AM
Jul-14-26 06:07PM
Jul-13-26 01:54PM
03:00AM
Jul-10-26 07:55AM
Jul-09-26 09:47AM
Jul-06-26 04:30PM
12:11PM
Jul-03-26 08:20AM
Jul-02-26 10:46AM
Jul-01-26 04:30PM
Jun-30-26 08:49AM
Jun-17-26 10:00AM
05:30AM
(The Wall Street Journal)
Jun-16-26 11:44AM
Jun-05-26 04:20PM
Jun-04-26 12:38PM
Jun-01-26 04:54AM
May-20-26 09:43AM
09:35AM
May-04-26 02:10PM
Apr-30-26 08:00AM
Apr-29-26 02:06PM
07:34AM
Apr-23-26 08:03AM
03:02AM
Apr-22-26 07:55AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
LAVU RATNAKAR EVP & Chief Digital Info Ofr Nov 05 '26 Sale 440.00 1,300 572,000 14,849 Nov 06 04:32 PM RATNAKAR LAVU Officer Nov 05 '26 Proposed Sale 440.00 1,300 572,000 Nov 05 04:13 PM Kaye Mark EVP & CFO Oct 22 '26 Sale 440.13 10,584 4,658,357 19,919 Oct 23 04:30 PM MARK B KAYE Officer Oct 22 '26 Proposed Sale 440.13 10,584 4,658,378 Oct 22 04:03 PM PERU RAMIRO G Director Jul 17 '26 Buy 366.05 1,000 366,050 10,908 Jul 17 03:04 PM BOUDREAUX GAIL President and CEO Jul 17 '26 Buy 367.79 2,725 1,002,230 171,976 Jul 17 01:50 PM CLARK R KERRY Director Jul 07 '26 Proposed Sale 419.91 1,500 629,865 Jul 07 04:58 PM Penczek Ronald W CAO & Controller Jun 12 '26 Sale 403.16 369 148,766 3,740 Jun 15 04:10 PM RONALD WILLIAM PENCZEK Officer Jun 12 '26 Proposed Sale 403.16 369 148,767 Jun 12 05:27 PM Dixon Robert L JR Director Jun 11 '26 Sale 401.77 151 60,667 10,734 Jun 12 04:12 PM Dixon Robert L JR Director Jun 11 '26 Proposed Sale 401.76 151 60,666 Jun 11 05:10 PM Penczek Ronald W CAO & Controller May 19 '26 Option Exercise 294.30 1,531 450,579 5,640 May 20 04:11 PM Penczek Ronald W CAO & Controller May 19 '26 Sale 403.13 1,531 617,192 4,109 May 20 04:11 PM RONALD WILLIAM PENCZEK Officer May 19 '26 Proposed Sale 403.13 1,531 617,192 May 19 04:25 PM SCHULMAN AMY W Director Mar 12 '26 Sale 287.50 26 7,475 218 Mar 23 04:10 PM Kendrick Charles Morgan JR EVP & President, Commercial Mar 06 '26 Sale 284.92 3,196 910,604 11,791 Mar 09 04:45 PM CHARLES MORGAN KENDRICK Officer Mar 06 '26 Proposed Sale 284.92 3,196 910,593 Mar 06 04:17 PM COLLIS STEVEN H Director Mar 05 '26 Buy 289.84 3,000 869,520 3,639 Mar 06 08:03 AM
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.
President Ms. Gail Koziara Boudreaux
Executive VP & CFO Mr. Mark Bradley Kaye
Special Advisor Mr. Peter David Haytaian Esq.
EVP and President of Commercial & Specialty Health Benefits Mr. Charles Morgan Kendrick Jr.
Executive VP & Chief Health Benefits Officer Ms. Felicia Farr Norwood